๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Considerations for Endpoint Selection When Designing HIV Clinical Trials

โœ Scribed by Katherine Huppler Hullsiek; Birgit Grund

Book ID
107542935
Publisher
Springer
Year
2011
Tongue
English
Weight
200 KB
Volume
14
Category
Article
ISSN
1523-3847

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

Endpoints and clinical trial design for
Endpoints and clinical trial design for nonalcoholic steatohepatitis
โœ Arun J. Sanyal; Elizabeth M. Brunt; David E. Kleiner; Kris V. Kowdley; Naga Chal ๐Ÿ“‚ Article ๐Ÿ“… 2011 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 155 KB ๐Ÿ‘ 1 views

Nonalcoholic fatty liver disease is a common cause of chronic liver disease in the general population. Nonalcoholic steatohepatitis (NASH), the aggressive form of nonalcoholic fatty liver disease, is associated with an increased risk of liver-related mortality and cardiovascular disease. At present,

American association for the study of li
American association for the study of liver diseases endpoints conference: Design and endpoints for clinical trials in primary biliary cirrhosis
โœ Marina G. Silveira; Elizabeth M. Brunt; Jenny Heathcote; Gregory J. Gores; Keith ๐Ÿ“‚ Article ๐Ÿ“… 2010 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 143 KB ๐Ÿ‘ 1 views

A group of multidisciplinary experts on primary biliary cirrhosis (PBC) and its complications convened on May 31, 2009, under the aegis of the American Association for the Study of Liver Diseases (AASLD) in order to identify the most appropriate design and endpoints for clinical trials of PBC based